{"id":"https://genegraph.clinicalgenome.org/r/b9c67219-0f3d-4b3b-a4c6-328451e77811v1.1","type":"EvidenceStrengthAssertion","dc:description":"The BANF1 gene is located on chromosome 11 at 11q13.1 and encodes the barrier to autointegration nuclear assembly factor 1 protein, a non-specific DNA-binding protein that plays key roles in mitotic nuclear reassembly, chromatin organization, DNA damage response, gene expression and intrinsic immunity against foreign DNA. BANF1 was first reported in relation to autosomal recessive NÃ©stor-Guillermo Progeria Syndrome (NGPS) in 2011 (Puente et al., PMID: 21549337;). NGPS is a unique progeria with a relatively long lifespan with features such as signs of aging, growth delay, reduced subcutaneous fat, decreased diameter of limbs, and stiffening of the joints. Per criteria outlined by the ClinGen Lumping and Splitting Working Group, we found clear differences in inheritance pattern and phenotypic variability between the following disease entities which have therefore been split: autosomal recessive NGPS and BANF1-related neurodevelopmental disorder. The split curation for autosomal dominant BANF1-related neurodevelopmental disorder has been curated separately.\n\nOne missense variant (possible founder variant in Spanish families) that has been reported in 3 probands in 2 publications (PMIDs: 21549337, 32783369) is included in this curation. The mechanism of pathogenicity appears to be loss-of-function. This gene-disease relationship is also supported by experimental evidence, including protein interaction and biochemical functional evidence, specifically interaction evidence with lamin, and function in DNA stability/repair activity (PMIDs: 36039758, 33660778). In summary, there is limited evidence supporting the relationship between BANF1 and autosomal recessive NGPS. Although more evidence is needed to support a causal role, no convincing evidence has emerged that contradicts the gene-disease relationship. This classification was approved by the ClinGen Syndromic Disorders GCEP on the meeting date April 3rd, 2024 (SOP Version 10).","dc:isVersionOf":"https://genegraph.clinicalgenome.org/r/b9c67219-0f3d-4b3b-a4c6-328451e77811","GCISnapshot":"https://genegraph.clinicalgenome.org/r/2e2059e5-b7a5-42fe-93b7-182982608431","calculatedEvidenceStrength":"Limited","changes":{"id":"cg:sopChange"},"contributions":[{"id":"https://genegraph.clinicalgenome.org/r/2e2059e5-b7a5-42fe-93b7-182982608431_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10060","date":"2024-04-03T16:00:00.000Z","role":"Approver"},{"id":"https://genegraph.clinicalgenome.org/r/2e2059e5-b7a5-42fe-93b7-182982608431_publish_contrib","agent":"https://genegraph.clinicalgenome.org/agent/10060","date":"2024-09-26T14:25:23.351Z","role":"Publisher"}],"curationReasons":["NewCuration"],"evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2e2059e5-b7a5-42fe-93b7-182982608431_overall_genetic_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/53b67842-fd6b-46ef-824f-8ee81fbe4d5c_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/53b67842-fd6b-46ef-824f-8ee81fbe4d5c","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32783369","rdfs:label":"Fisher p.Ala12Thr proband ","ageType":"AgeAtReport","ageUnit":"Years","ageValue":2,"allele":{"id":"https://genegraph.clinicalgenome.org/r/de92d078-43d2-41a2-a6e5-c5e31200aaa5","type":"https://terms.ga4gh.org/VariationDescriptor","http://www.w3.org/2004/02/skos/core#prefLabel":"NM_003860.4(BANF1):c.34G>A (p.Ala12Thr)","https://terms.ga4gh.org/CanonicalReference":{"id":"http://reg.genome.network/allele/CA129181"}},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"respiratory distress in the first 24 hours of life; early eruption of teeth (full set by age 1); weight (8.5 kg) and height (80 cm), each notably below 3rd percentile\n","phenotypes":["obo:HP_0002643","obo:HP_0000460","obo:HP_0002293","obo:HP_0010539","obo:HP_0002797","obo:HP_0011800","obo:HP_0001518","obo:HP_0001156","obo:HP_0006288","obo:HP_0007651","obo:HP_0001500","obo:HP_0030799","obo:HP_0000252"],"sex":"Female","variant":{"id":"https://genegraph.clinicalgenome.org/r/8950bf74-f3ad-436d-a2a3-85390f290bd2_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/32783369","allele":{"id":"https://genegraph.clinicalgenome.org/r/de92d078-43d2-41a2-a6e5-c5e31200aaa5"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/8950bf74-f3ad-436d-a2a3-85390f290bd2","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8950bf74-f3ad-436d-a2a3-85390f290bd2_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/8950bf74-f3ad-436d-a2a3-85390f290bd2_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Patient fibroblasts had notably decreased expression of BAF than the controls or the heterozygous carrier, the latter of which had moderate levels of BAF. mRNA levels were not substantially altered in the mutant fibroblasts, showing that the mutation impacts protein stability instead of mRNA expression. \n","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/159f2ce1-fc90-4a26-90dc-8ca02558d75d_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/159f2ce1-fc90-4a26-90dc-8ca02558d75d","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21549337","rdfs:label":"p.Ala12Thr Puente proband 1 ","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":2,"allele":{"id":"https://genegraph.clinicalgenome.org/r/de92d078-43d2-41a2-a6e5-c5e31200aaa5"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"small light-brown spots over thorax, scalp, and limbs; pronounced osteolysis (mandible, clavicles, ribs, distal phalanges, and radius); had significant loss of scalp hair starting at age 12","phenotypes":["obo:HP_0005897","obo:HP_0002293","obo:HP_0000444","obo:HP_0002650","obo:HP_0000520","obo:HP_0001001","obo:HP_0000958","obo:HP_0004334","obo:HP_0001000","obo:HP_0002797","obo:HP_0100578","obo:HP_0000347"],"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/aff72dca-91fc-4138-9d65-341ee4878370_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21549337","allele":{"id":"https://genegraph.clinicalgenome.org/r/de92d078-43d2-41a2-a6e5-c5e31200aaa5"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/aff72dca-91fc-4138-9d65-341ee4878370","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/aff72dca-91fc-4138-9d65-341ee4878370_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/aff72dca-91fc-4138-9d65-341ee4878370_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Patient fibroblasts had notably decreased expression of BAF than the controls or the heterozygous carrier, the latter of which had moderate levels of BAF. mRNA levels were not substantially altered in the mutant fibroblasts, showing that the mutation impacts protein stability instead of mRNA expression. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0},{"id":"https://genegraph.clinicalgenome.org/r/8b6c16d9-ab83-4161-932a-94fc8497ca5a_proband_score_evidence_line","type":"EvidenceLine","direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/8b6c16d9-ab83-4161-932a-94fc8497ca5a","type":"Proband","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21549337","rdfs:label":"p.Ala12Thr Puente proband 2","ageType":"AgeAtOnset","ageUnit":"Years","ageValue":2,"allele":{"id":"https://genegraph.clinicalgenome.org/r/de92d078-43d2-41a2-a6e5-c5e31200aaa5"},"firstTestingMethod":"Exome sequencing","phenotypeFreeText":"scoliosis was mild ","phenotypes":["obo:HP_0002650","obo:HP_0011712","obo:HP_0011703","obo:HP_0002645","obo:HP_0002280","obo:HP_0000278","obo:HP_0008897","obo:HP_0001510","obo:HP_0031846","obo:HP_0002293","obo:HP_0005897","obo:HP_0000678"],"sex":"Male","variant":{"id":"https://genegraph.clinicalgenome.org/r/ffad0219-ac19-4af8-971a-5daa8ebf085d_variant_evidence_item","type":"VariantObservation","dc:source":"https://pubmed.ncbi.nlm.nih.gov/21549337","allele":{"id":"https://genegraph.clinicalgenome.org/r/de92d078-43d2-41a2-a6e5-c5e31200aaa5"},"alleleOrigin":{"id":"cg:GermlineAlleleOrigin"},"zygosity":{"id":"cg:Homozygous"}}},{"id":"https://genegraph.clinicalgenome.org/r/ffad0219-ac19-4af8-971a-5daa8ebf085d","type":"EvidenceLine","calculatedScore":1.0,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/ffad0219-ac19-4af8-971a-5daa8ebf085d_variant_evidence_item"},{"id":"https://genegraph.clinicalgenome.org/r/ffad0219-ac19-4af8-971a-5daa8ebf085d_function_evidence_item","type":"VariantFunctionalImpactEvidence","dc:description":"Patient fibroblast analysis: Patient fibroblasts had notably decreased expression of BAF than the controls or the heterozygous carrier, the latter of which had moderate levels of BAF. mRNA levels were not substantially altered in the mutant fibroblasts, showing that the mutation impacts protein stability instead of mRNA expression. ","functionalDataSupport":"Yes"}],"specifiedBy":"GeneValidityNonNullVariantCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityMaximumProbandScoreCriteria","strengthScore":1.0}],"specifiedBy":"GeneValidityOverallGeneticEvidenceCriteria","strengthScore":3},{"id":"https://genegraph.clinicalgenome.org/r/2e2059e5-b7a5-42fe-93b7-182982608431_experimental_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/2e2059e5-b7a5-42fe-93b7-182982608431_functional_evidence_line","type":"EvidenceLine","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/be296074-5711-4055-b88f-af8f7bc06a39","type":"EvidenceLine","dc:description":"Lamin A/C has not been curated for this specific condition (NGPS), but is associated with aging, which is the main phenotype of NGPS. ","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/840fb677-2452-47c8-90f3-d1a72501518b","type":"Finding","dc:description":"Interaction with lamin A/C is inhibited by the p.Ala12Thr mutation, compared to the control, but this interaction can be restored via over-expression of wild-type BAF.  \n","dc:source":"https://pubmed.ncbi.nlm.nih.gov/36039758","rdfs:label":"Interaction with lamin","demonstrates":{"id":"obo:MI_0915"}}],"specifiedBy":"GeneValidityProteinInteractionCriteria","strengthScore":0.5},{"id":"https://genegraph.clinicalgenome.org/r/feb7289d-c6e4-42dc-85f6-463e41d3c03b","type":"EvidenceLine","calculatedScore":0.5,"direction":"Supports","evidence":[{"id":"https://genegraph.clinicalgenome.org/r/b8b18992-b7da-4c87-bbc5-f00ebad07563","type":"Finding","dc:description":"Abnormality of DNA repair is linked to aging, which is the main phenotype of NGPS. ","dc:source":"https://pubmed.ncbi.nlm.nih.gov/33660778","rdfs:label":"DNA pyruvate kinase/DNA repair activity","demonstrates":{"id":"cg:BiochemicalFunctionB"}}],"specifiedBy":"GeneValidityBiochemicalFunctionCriteria","strengthScore":0.5}],"specifiedBy":"GeneValidityOverallFunctionalEvidenceCriteria","strengthScore":1}],"specifiedBy":"GeneValidityOverallExperimentalEvidenceCriteria","strengthScore":1}],"evidenceStrength":"Limited","sequence":9025,"specifiedBy":"GeneValidityCriteria10","strengthScore":4,"subject":{"id":"https://genegraph.clinicalgenome.org/r/WUOkIfOV1l4","type":"GeneValidityProposition","disease":"obo:MONDO_0013523","gene":"hgnc:17397","modeOfInheritance":"obo:HP_0000007"},"version":"1.1","websiteLegacyID":"https://genegraph.clinicalgenome.org/r/assertion_2e2059e5-b7a5-42fe-93b7-182982608431-","@context":{"@vocab":"https://genegraph.clinicalgenome.org/terms/","id":"@id","type":"@type","cg":"https://genegraph.clinicalgenome.org/terms/","dc":"http://purl.org/dc/terms/","obo":"http://purl.obolibrary.org/obo/","hgnc":"https://identifiers.org/hgnc:","rdfs":"http://www.w3.org/2000/01/rdf-schema#","cggv":"https://genegraph.clinicalgenome.org/r/gci/","evidenceStrength":{"@type":"@vocab"},"calculatedEvidenceStrength":{"@type":"@vocab"},"computedEvidenceStrength":{"@type":"@vocab"},"specifiedBy":{"@type":"@vocab"},"evidence":{"@container":"@set"},"disease":{"@type":"@vocab"},"gene":{"@type":"@vocab"},"phenotypes":{"@type":"@id"},"agent":{"@type":"@id"},"role":{"@type":"@vocab"},"modeOfInheritance":{"@type":"@vocab"},"sex":{"@type":"@vocab"},"direction":{"@type":"@vocab"},"ageType":{"@type":"@vocab"},"ageUnit":{"@type":"@vocab"},"dc:source":{"@type":"@id"},"curationReasons":{"@type":"@vocab","@container":"@set"},"GCISnapshot":{"@type":"@id"},"dc:isVersionOf":{"@type":"@id"},"websiteLegacyID":{"@type":"@id"}}}